Evidence map›Paper›PMID 35858545›Full record

ArticleCell reports2022

Mutant KRAS regulates transposable element RNA and innate immunity via KRAB zinc-finger genes.

Roman E Reggiardo, Sreelakshmi Velandi Maroli, Haley Halasz, Mehmet Ozen, Eva Hrabeta-Robinson, Amit Behera, Vikas Peddu, David Carrillo, Erin LaMontagne, Lila Whitehead and 8 more

Open access · goldAbstract read
In one paragraph

Article in Cell reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Targeting KRAS Inhibitor-Resistant Pancreatic Cancer with an MUC1-C Antibody-Drug Conjugate.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 1 country.

Roman E ReggiardoDepartment of Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, CA 95064, USA.
Sreelakshmi Velandi MaroliDepartment of Molecular, Cell, and Developmental Biology, University of California, Santa Cruz, Santa Cruz, CA 95064, USA.
Haley HalaszDepartment of Molecular, Cell, and Developmental Biology, University of California, Santa Cruz, Santa Cruz, CA 95064, USA.
Mehmet OzenCanary Center at Stanford for Cancer Early Detection, Department of Radiology, Stanford University School of Medicine, Palo Alto, CA 94305, USA.
Eva Hrabeta-RobinsonDepartment of Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, CA 95064, USA.
Amit BeheraDepartment of Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, CA 95064, USA.
Vikas PedduDepartment of Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, CA 95064, USA.
David CarrilloDepartment of Molecular, Cell, and Developmental Biology, University of California, Santa Cruz, Santa Cruz, CA 95064, USA.
Erin LaMontagneDepartment of Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, CA 95064, USA.
Lila WhiteheadDepartment of Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, CA 95064, USA.
Eejung KimBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Shivani MalikDepartment of Medicine, University of California, San Francisco, San Francisco, CA 94158, USA.
Jason FernandesDepartment of Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, CA 95064, USA.
Georgi MarinovDepartment of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA.
Eric CollissonDepartment of Medicine, University of California, San Francisco, San Francisco, CA 94158, USA.
Angela BrooksDepartment of Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, CA 95064, USA; Genomics Institute, University of California, Santa Cruz, Santa Cruz, CA 95064, USA; Center for Molecular Biology of RNA, University of California, Santa Cruz, Santa Cruz, CA 95064, USA.
Utkan DemirciCanary Center at Stanford for Cancer Early Detection, Department of Radiology, Stanford University School of Medicine, Palo Alto, CA 94305, USA.
Daniel H KimDepartment of Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, CA 95064, USA; Canary Center at Stanford for Cancer Early Detection, Department of Radiology, Stanford University School of Medicine, Palo Alto, CA 94305, USA; Institute for the Biology of Stem Cells, University of California, Santa Cruz, Santa Cruz, CA 95064, USA; Genomics Institute, University of California, Santa Cruz, Santa Cruz, CA 95064, USA; Center for Molecular Biology of RNA, University of California, Santa Cruz, Santa Cruz, CA 95064, USA. Electronic address: daniel.kim@ucsc.edu.
University of California, Santa Cruz · USStanford University · USUniversity of California, San Francisco · USBroad Institute · US

Funding

Genomics and Functional Characterization of NF1-mutated Lung CancerR01CA227807 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COLLISSON, ERIC · 2018 to 2022
$2.8M
The structural and functional basis of MET exon 14 activation and acquired drug resistanceR01CA230263 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COLLISSON, ERIC, JURA, NATALIA · 2019 to 2023
$2.0M
Optimizing Treatment Approaches to Lung Cancers Harboring MET Exon 14 mutationsR01CA239604 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COLLISSON, ERIC · 2019 to 2023
$2.0M
Cell free RNA liquid biopsiesF99DK131504 · NIDDK · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI REGGIARDO, ROMAN E · 2021 to 2022
$88k
NCI NIH HHS R01 CA227807NCI NIH HHS R01 CA230263NCI NIH HHS R01 CA239604NIDDK NIH HHS F99 DK131504
6 · The paper itself

Abstract

RAS genes are the most frequently mutated oncogenes in cancer, yet the effects of oncogenic RAS signaling on the noncoding transcriptome remain unclear. We analyzed the transcriptomes of human airway and bronchial epithelial cells transformed with mutant KRAS to define the landscape of KRAS-regulated noncoding RNAs. We find that oncogenic KRAS signaling upregulates noncoding transcripts throughout the genome, many of which arise from transposable elements (TEs). These TE RNAs exhibit differential expression, are preferentially released in extracellular vesicles, and are regulated by KRAB zinc-finger (KZNF) genes, which are broadly downregulated in mutant KRAS cells and lung adenocarcinomas in vivo. Moreover, mutant KRAS induces an intrinsic IFN-stimulated gene (ISG) signature that is often seen across many different cancers. Our results indicate that mutant KRAS remodels the repetitive noncoding transcriptome, demonstrating the broad scope of intracellular and extracellular RNAs regulated by this oncogenic signaling pathway.

Indexed as

DNA Transposable ElementsGenes, rasCell Line, TumorHumansImmunity, InnateMutationProto-Oncogene Proteins p21(ras)RNAZincDNA Transposable ElementsKRAS protein, humanProto-Oncogene Proteins p21(ras)RNAZinccancerCP: Molecular biologyextracellular RNAextracellular vesiclesinterferon-stimulated genesKRASKZNFnoncoding RNARAS signalingRNA biomarkertransposable element

Identifiers

PMID35858545
PMCPMC9374308
OpenAlexW4286252354

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.